👤 Wenyuan Zhao

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1404
Articles
874
Name variants
Also published as: A N Zhao, Ahui Zhao, Ai Zhao, Aihua Zhao, Aimin Zhao, Andrea Zhao, Andrew J Zhao, Anna Zhao, Aonan Zhao, B Zhao, Bangzhe Zhao, Baolin Zhao, Baosheng Zhao, Baoyu Zhao, Bei Zhao, Bei-Bei Zhao, Beibei Zhao, Beichuan Zhao, Bi Zhao, Bin Zhao, Bing-Qian Zhao, Bingcong Zhao, Binggong Zhao, Binghai Zhao, Bingli Zhao, Bingru Zhao, Bishi Zhao, Bo Zhao, Bo-Wen Zhao, Caifeng Zhao, Caiping Zhao, Caiqi Zhao, Chang Zhao, Changle Zhao, Changqing Zhao, Changsheng Zhao, Changzhi Zhao, Chao Zhao, Chaofen Zhao, Chaoyue Zhao, Chen Zhao, Chen-Guang Zhao, Chen-Liang Zhao, Chen-Xi Zhao, Chenchen Zhao, Cheng Zhao, Cheng-Long Zhao, Chengcheng Zhao, Chengjian Zhao, Chengjun Zhao, Chengrui Zhao, Chengshui Zhao, Chenming Zhao, Chenxu Zhao, Chenye Zhao, Chuan Zhao, Chuan-Zhi Zhao, Chuanqi Zhao, Chun Yu Zhao, Chun-Hui Zhao, Chunjie Zhao, Chunli Zhao, Chunqing Zhao, Chunrong Zhao, Chuntao Zhao, Chunyan Zhao, Chuo Zhao, Cong Zhao, Cuifen Zhao, Cuimei Zhao, Cuiqing Zhao, Cun Zhao, D C Zhao, Dan Zhao, Dandan Zhao, Danping Zhao, Danrui Zhao, Danyang Zhao, Daqing Zhao, Dawang Zhao, Dawen Zhao, Dechang Zhao, Defeng Zhao, Dekuang Zhao, Dengyun Zhao, Deping Zhao, Di Zhao, Dingmeng Zhao, Dingwei Zhao, Dingying Zhao, Dong Zhao, Dong-Dong Zhao, Dongbao Zhao, Dongfeng Zhao, Dongmei Zhao, Dongping Zhao, En-chun Zhao, Ende Zhao, F Zhao, Fan Zhao, Fang Zhao, Fangfang Zhao, Fangjue Zhao, Fangli Zhao, Fangping Zhao, Fangyi Zhao, Fangyu Zhao, Faye Zhao, Fei Zhao, Feibo Zhao, Feipeng Zhao, Feitao Zhao, Feng Zhao, Fengbo Zhao, Fengdi Zhao, Fenghui Zhao, Fengshu Zhao, Fu-Ying Zhao, Fuping Zhao, Fuyu Zhao, Gaichao Zhao, Gang Zhao, Gaofeng Zhao, Ge-Xin Zhao, Gengxiang Zhao, Guang-Hui Zhao, Guangfeng Zhao, Guanghao Zhao, Guanghui Zhao, Guangqiang Zhao, Guangshan Zhao, Guangyuan Zhao, Gui Zhao, Guifang Zhao, Guihu Zhao, Guile Zhao, Guiping Zhao, Guizhen Zhao, Guo-Jun Zhao, Guoqing Zhao, Guorui Zhao, Guozhi Zhao, Haifeng Zhao, Hailing Zhao, Haiquan Zhao, Hairong Zhao, Haixin Zhao, Haiyan Zhao, Haizhou Zhao, Han Zhao, Hanhan Zhao, Hanjun Zhao, Hanqing Zhao, Hao Zhao, Haonan Zhao, Haoyan Zhao, He Zhao, Heng Zhao, Hengxia Zhao, Hong Zhao, Hong-Bo Zhao, Hong-Yang Zhao, Hong-Ye Zhao, Hongbin Zhao, Hongbo Zhao, Hongda Zhao, Hongfeng Zhao, Honghui Zhao, Hongli Zhao, Hongling Zhao, Hongmei Zhao, Hongmeng Zhao, Hongqi Zhao, Hongqing Zhao, Hongwei Zhao, Hongxia Zhao, Hongyan Zhao, Hongyi Zhao, Hongying Zhao, Hongyu Zhao, Houyu Zhao, Hu Zhao, Hua Zhao, Huadong Zhao, Huakan Zhao, Huan Zhao, Huan-Yu Zhao, Huanxin Zhao, Huanyu Zhao, Huaqing Zhao, Huashan Zhao, Huaying Zhao, Hui Zhao, Hui-Hui Zhao, Huihan Zhao, Huiijin Zhao, Huili Zhao, Huilin Zhao, Huiling Zhao, Huishou Zhao, Huiying Zhao, Huiyong Zhao, J H Zhao, J V Zhao, J Zhao, J-F Zhao, Jean J Zhao, Ji Zhao, Ji-Meng Zhao, Ji-jun Zhao, Jia Zhao, Jia-Li Zhao, Jia-Mu Zhao, Jia-Xuan Zhao, Jia-Yi Zhao, Jia-jun Zhao, Jiabin Zhao, Jiajing Zhao, Jiale Zhao, Jialin Zhao, Jian Zhao, Jian-Yuan Zhao, Jian-hua Zhao, Jianan Zhao, Jiang Zhao, Jiangchao Zhao, Jiangpei Zhao, Jianguo Zhao, Jianhong Zhao, Jianhua Zhao, Jianjun Zhao, Jianrong Zhao, Jianwen Zhao, Jianxin Zhao, Jianzhi Zhao, Jiao Zhao, Jiaxuan Zhao, Jichen Zhao, Jie V Zhao, Jie Zhao, Jie-Dong Zhao, Jie-Jun Zhao, Jiexiang Zhao, Jiexiu Zhao, Jieyu Zhao, Jieyun Zhao, Jikai Zhao, Jin Zhao, Jin-Feng Zhao, Jin-Ming Zhao, Jinbo Zhao, Jincun Zhao, Jinfang Zhao, Jing Hau Zhao, Jing Hua Zhao, Jing Zhao, Jing-Cheng Zhao, Jing-Feng Zhao, Jing-Jing Zhao, Jing-Yi Zhao, Jing-Yu Zhao, JingLi Zhao, JingTing Zhao, Jingbo Zhao, Jingjie Zhao, Jingjing Zhao, Jingkun Zhao, Jinglin Zhao, Jingru Zhao, Jingtai Zhao, Jingtong Zhao, Jingya Zhao, Jingyi Zhao, Jingying Zhao, Jingyuan Zhao, Jinjing Zhao, Jinlan Zhao, Jinmin Zhao, Jinpeng Zhao, Jinping Zhao, Jinshan Zhao, Jinsheng Zhao, Jinwen Zhao, Jinyao Zhao, Jiong-Yao Zhao, Jiwei Zhao, Jizong Zhao, Juan Zhao, Juanjuan Zhao, Jue Zhao, Jun Zhao, Jun-Hui Zhao, Junfeng Zhao, Junhong Zhao, Junjie Zhao, Junkang Zhao, Junli Zhao, Junqin Zhao, Junzhang Zhao, Kai Zhao, Kaidong Zhao, Kaihui Zhao, Kaikai Zhao, Kaiyue Zhao, Kake Zhao, Kangqi Zhao, Ke Zhao, Ke-Xin Zhao, Keji Zhao, Keni Zhao, Keqin Zhao, Kewen Zhao, Kun Zhao, L Zhao, Lan Zhao, Lanhua Zhao, Le Zhao, Lei Zhao, Leyang Zhao, Leying Zhao, Li Feng Zhao, Li Zhao, Li-Bo Zhao, Li-Feng Zhao, Li-Hua Zhao, Li-Li Zhao, Li-Mei Zhao, Li-ke Zhao, Lianfang Zhao, Liang Zhao, Liang-gong Zhao, Liangyu Zhao, Lianhua Zhao, Lianmei Zhao, Liansheng Zhao, Lichun Zhao, Lihua Zhao, Lijia Zhao, Lijian Zhao, Lijuan Zhao, Lijun Zhao, Lili Zhao, Limei Zhao, Liming Zhao, Lin Yi Zhao, Lin Zhao, Lina Zhao, Ling Zhao, Ling-Ling Zhao, Lingling Zhao, Lingqiang Zhao, Lingrui Zhao, Linhai Zhao, Linhua Zhao, Linlin Zhao, Liping Zhao, Liqin Zhao, Liwei Zhao, Long Zhao, Longhe Zhao, Lu Zhao, Lujun Zhao, Lun Zhao, Luo-Sha Zhao, Luqi Zhao, Luyao Zhao, M Zhao, Mai Zhao, Mei Zhao, Meifang Zhao, Meiqi Zhao, Meng Zhao, Mengjia Zhao, Mengjie Zhao, Mengmeng Zhao, Mengshu Zhao, Mengxi Zhao, Mengya Zhao, Michelle Zhao, Min Zhao, Mindi Zhao, Ming Zhao, Ming-Gao Zhao, Ming-Tao Zhao, Mingjing Zhao, Mingjun Zhao, Mingming Zhao, Mingwei Zhao, Mingyue Zhao, Mo Zhao, Moze Zhao, N Zhao, Na Zhao, Na-Na Zhao, Nan Zhao, Ning Zhao, Ningkang Zhao, Pandeng Zhao, Peijun Zhao, Peinan Zhao, Peipei Zhao, Peishen Zhao, Peng Zhao, Pengjun Zhao, Ping Zhao, Pingfan Zhao, Pu Zhao, Qi Zhao, Qian Zhao, Qiancheng Zhao, Qianhua Zhao, Qianjun Zhao, Qianyi Zhao, Qihan Zhao, Qilin Zhao, Qin Zhao, Qin-Shi Zhao, Qinfei Zhao, Qing Zhao, Qing-Chun Zhao, Qing-Li Zhao, Qingbo Zhao, Qingchun Zhao, Qinghe Zhao, Qingqing Zhao, Qingshi Zhao, Qingwen Zhao, Qingzuo Zhao, Qiong Zhao, Qiongxian Zhao, Qiongyi Zhao, Qiqi Zhao, Qitao Zhao, Qiuyue Zhao, Quan Zhao, Quanzhen Zhao, Ran Zhao, Ranran Zhao, Ranzun Zhao, Ren Zhao, Renfeng Zhao, Renjia Zhao, Richard L Zhao, Rong Jie Zhao, Rong Zhao, Rui Zhao, Ruidan Zhao, Ruiqi Zhao, Ruixuan Zhao, Ruizhen Zhao, Runming Zhao, Ruohan Zhao, Ruojin Zhao, Ruxun Zhao, Ruyi Zhao, S H Zhao, S S Zhao, S-P Zhao, Sha Zhao, Shan-Shan Zhao, Shane R Zhao, Shanshan Zhao, Shanzhi Zhao, Shao-Zhen Zhao, Shaorong Zhao, Shaoyang Zhao, Sheng Zhao, Shengguo Zhao, Shengjun Zhao, Shenjun Zhao, Shi Zhao, Shi-Min Zhao, Shigang Zhao, Shihua Zhao, Shiji Zhao, Shimiao Zhao, Shitian Zhao, Shiwei Zhao, Shu-Ning Zhao, Shuai Zhao, Shuang Zhao, Shuang-Qiao Zhao, Shuangshuang Zhao, Shuangxia Zhao, Shuanping Zhao, Shufen Zhao, Shui-ping ZHAO, Shuiping Zhao, Shujuan Zhao, Shuliang Zhao, Shunying Zhao, Shuqiang Zhao, Shuxuan Zhao, Shuyue Zhao, Shuzhen Zhao, Shuzhi Zhao, Si-Jia Zhao, Sihai Zhao, Siqi Zhao, Sitong Zhao, Siyuan Zhao, Song Zhao, Song-Song Zhao, Songchen Zhao, Songping Zhao, Steven Zhao, Suonan Zhao, Suwen Zhao, T C Zhao, Tanjun Zhao, Tian Zhao, Tian-Yu Zhao, Tiancheng Zhao, Tianjing Zhao, Tianna Zhao, Tianyang Zhao, Tianyong Zhao, Tianyu Zhao, Tieqiang Zhao, Tiesuo Zhao, Ting C Zhao, Ting Zhao, Tingrui Zhao, Tingting Zhao, Tong Zhao, Tongfeng Zhao, W S Zhao, W Zhao, W-C Zhao, Wang ZHAO, Wang-Sheng Zhao, Wanglin Zhao, Wangsheng Zhao, Wanni Zhao, Wanqiu Zhao, Wanting Zhao, Wanxin Zhao, Wei Zhao, Wei-Li Zhao, Wei-Qian Zhao, Weichao Zhao, Weifeng Zhao, Weikun Zhao, Weimin Zhao, Weina Zhao, Weipeng Zhao, Weiqi Zhao, Weisong Zhao, Weiwei Zhao, Weixin Zhao, Weiyu Zhao, Weiyue Zhao, Wen Zhao, Wen-Ning Zhao, Wen-qiu Zhao, Wencai Zhao, Wenchen Zhao, Wenhong Zhao, Wenhua Zhao, Wenjing Zhao, Wenjuan Zhao, Wenjun Zhao, Wenming Zhao, Wenpeng Zhao, Wenshan Zhao, Wenshu Zhao, Wensi Zhao, Wenting Zhao, Wenxin Zhao, Wenxu Zhao, Wenye Zhao, Wenyu Zhao, Wukui Zhao, X S Zhao, X Zhao, Xi Zhao, Xi-Yu Zhao, Xia Zhao, Xian Zhao, Xiang Zhao, Xiang-Hui Zhao, Xiangdong Zhao, Xiangge Zhao, Xianghu Zhao, Xianglong Zhao, Xiangqin Zhao, Xiao Zhao, Xiao-Fan Zhao, Xiao-Fang Zhao, Xiao-Jie Zhao, Xiao-Jing Zhao, Xiao-Ning Zhao, Xiao-Yu Zhao, XiaoQing Zhao, Xiaodong Zhao, Xiaoduo Zhao, Xiaofang Zhao, Xiaofei Zhao, Xiaoguang Zhao, Xiaohan Zhao, Xiaohang Zhao, Xiaohong Zhao, Xiaohui Zhao, Xiaojun Zhao, Xiaoli Zhao, Xiaoling Zhao, Xiaoming Zhao, Xiaopei Zhao, Xiaopeng Zhao, Xiaoqiang Zhao, Xiaoqin Zhao, Xiaowen Zhao, Xiaoxi Zhao, Xiaoyan Zhao, Xiaoyang Zhao, Xiaoyao Zhao, Xiaoyu Zhao, Xiaoyuan Zhao, Xiaoyun Zhao, Xiaozhi Zhao, Xibao Zhao, Xilin Zhao, Xin Zhao, Xin-Yuan Zhao, Xincheng Zhao, Xing Zhao, Xing-Bo Zhao, Xingang Zhao, Xingbo Zhao, Xingsen Zhao, Xinguo Zhao, Xingwang Zhao, Xingyi Zhao, Xingyu Zhao, Xinhan Zhao, Xinhui Zhao, Xinjie Zhao, Xinlei Zhao, Xinming Zhao, Xinrui Zhao, Xinyang Zhao, Xinying Zhao, Xinyu Zhao, Xinyue Zhao, Xinzhi Zhao, Xipeng Zhao, Xitong Zhao, Xiu-Ju Zhao, Xiujuan Zhao, Xiuli Zhao, Xiumei Zhao, Xiumin Zhao, Xiurong Zhao, Xiutao Zhao, Xiuxin Zhao, Xiuyun Zhao, Xu Zhao, Xu-Zi Zhao, Xuan Zhao, Xudong Zhao, Xue-Li Zhao, Xue-Qiao Zhao, Xueli Zhao, Xueqing Zhao, Xuerong Zhao, Xuesong Zhao, Xueying Zhao, Xuli Zhao, Xunying Zhao, Y U Zhao, Y Z Zhao, Y Zhao, Ya Zhao, Yafei Zhao, Yahui Zhao, Yajie Zhao, Yali Zhao, Yan G Zhao, Yan Ting Zhao, Yan Zhao, Yan-Hong Zhao, Yan-Lin Zhao, Yan-Ni Zhao, Yanan Zhao, Yanbin Zhao, Yandong Zhao, Yanfei Zhao, Yang Zhao, Yangang Zhao, Yangqi Zhao, Yanhong Zhao, Yanhua Zhao, Yanhui Zhao, Yanli Zhao, Yanna Zhao, Yanni Zhao, Yanrong Zhao, Yanxiang Zhao, Yanyan Zhao, Yanyu Zhao, Yao Zhao, Yating Zhao, Yawei Zhao, Ye Zhao, Yeli Zhao, Yi Zhao, Yi-Fan Zhao, Yichao Zhao, Yifan Zhao, Yifang Zhao, Yiheng Zhao, Yijing Zhao, Yijun Zhao, Yikun Zhao, Yilin Zhao, Yiming Zhao, Yimu Zhao, Yin Zhao, Ying Ming Zhao, Ying Xin Zhao, Ying Zhao, Ying-Peng Zhao, Ying-Zheng Zhao, Yingchao Zhao, Yingdong Zhao, Yingmin Zhao, Yingming Zhao, Yingpeng Zhao, Yingqi Zhao, Yingxin Zhao, Yingying Zhao, Yingzheng Zhao, Yinlong Zhao, Yiqiang Zhao, Yisha Zhao, Yiwei Zhao, Yixia Zhao, Yixiu Zhao, Yixuan Zhao, Yixue Zhao, Yiyang Zhao, Yiyi Zhao, Yizhen Zhao, Yong Zhao, Yong-Liang Zhao, Yong-fang Zhao, Yongchao Zhao, Yongfei Zhao, Yongjian Zhao, Yongju Zhao, Yonglin Zhao, Yonglong Zhao, Yongqi Zhao, Yongqin Zhao, Yongting Zhao, Yongxia Zhao, Yongxiang Zhao, Yu Zhao, Yu-Cong Zhao, Yu-Lin Zhao, Yu-Xia Zhao, Yu-pei Zhao, Yuan Zhao, Yuan-Yuan Zhao, Yuanhui Zhao, Yuanji Zhao, Yuanjin Zhao, Yuanyin Zhao, Yuanyuan Zhao, Yuanzhi Zhao, Yubai Zhao, Yubo Zhao, Yuchen Zhao, Yudan Zhao, Yudi Zhao, Yue Zhao, Yue-Chao Zhao, Yuee Zhao, Yuehan Zhao, Yueyang Zhao, Yueying Zhao, Yufan Zhao, Yufei Zhao, Yuhang Zhao, Yuhong Zhao, Yuhui Zhao, Yujiao Zhao, Yujie Zhao, Yukui Zhao, Yulong Zhao, Yun Zhao, Yun-Li Zhao, Yun-Tao Zhao, Yunbo Zhao, Yunchao Zhao, Yunli Zhao, Yunwang Zhao, Yuqi Zhao, Yurong Zhao, Yuru Zhao, Yusen Zhao, Yuting Zhao, Yutong Zhao, Yuwen Zhao, Yuxi Zhao, Yuxia Zhao, Yuxiao Zhao, Yuxin Zhao, Yuyang Zhao, Yuzhen Zhao, Yuzheng Zhao, Z Zhao, Zaixu Zhao, Zanmei Zhao, Ze Hua Zhao, Ze-Hua Zhao, Ze-Run Zhao, Ze-Yu Zhao, Zeng-Ren Zhao, Zengqi Zhao, Zexi Zhao, Zhan Zhao, Zhanzheng Zhao, Zhao Zhao, Zhe Yu Zhao, Zhe Zhao, Zhen Zhao, Zhen-Long Zhao, Zhen-Wang Zhao, Zheng Zhao, Zhengjiang Zhao, Zhengyan Zhao, Zhenhua Zhao, Zhenlin Zhao, Zhensheng Zhao, Zhenyu Zhao, Zhi-Kun Zhao, Zhibo Zhao, Zhichao Zhao, Zhicong Zhao, Zhigang Zhao, Zhihao Zhao, Zhihe Zhao, Zhihui Zhao, Zhijian Zhao, Zhikang Zhao, Zhikun Zhao, Zhiming Zhao, Zhipeng Zhao, Zhiqiang Zhao, Zhiwei Zhao, Zhiying Zhao, Zhiyun Zhao, Zhongming Zhao, Zhongquan Zhao, Zhongxin Zhao, Zhuoyan Zhao, Zifeng Zhao, Zihan Zhao, Zihe Zhao, Zijia Zhao, Zijie Zhao, Zijin Zhao, Ziqi Zhao, Ziqin Zhao, Zirui Zhao, Zitong Zhao, Ziyi Zhao, Ziyu Zhao, Zongjiang Zhao, Zongren Zhao, Zongsheng Zhao, Zuhang Zhao
articles
M M Zhang, S S Zhao, N Huang +2 more · 2021 · Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn112150-20200824-01145
IL27
Jinling Huang, Hae-Youn Lee, Xiaohong Zhao +11 more · 2021 · Immunity · Elsevier · added 2026-04-24
The interleukin (IL)-17 family, consisting of six members, promotes host defense but can in some context promote the development of autoimmune disease. Here, we examined the role of IL-17D, a poorly u Show more
The interleukin (IL)-17 family, consisting of six members, promotes host defense but can in some context promote the development of autoimmune disease. Here, we examined the role of IL-17D, a poorly understood member in the IL-17 family. IL-17D was expressed primarily by colonic epithelial cells. Il17d Show less
no PDF DOI: 10.1016/j.immuni.2021.03.018
IL27
Chun Luo, Binru Li, Lang Chen +2 more · 2021 · Journal of molecular neuroscience : MN · Springer · added 2026-04-24
The occurrence of ischemia-reperfusion (I/R) injury leads to dysfunction as well as high rates of morbidity and mortality in stroke, and new effective therapeutic strategies for I/R are still needed. Show more
The occurrence of ischemia-reperfusion (I/R) injury leads to dysfunction as well as high rates of morbidity and mortality in stroke, and new effective therapeutic strategies for I/R are still needed. We investigated the effect of IL-27 on I/R injury-induced neurological function impairment, cerebral infarction volume and variation in levels of inflammatory factors in mice with middle cerebral artery occlusion (MCAO), as well as concentration of LDH and neuronal apoptosis in a neuron oxygen-glucose deprivation and reperfusion (OGD/R) model mediated by gp130/STAT3 signaling in vitro. Our results indicated that IL-27 could bind to its receptor of gp130 to attenuate the I/R injury-induced impairment function and cerebral infarction volume, and decrease inflammatory cytokines TNF-α, IL-1β and MCP-1 but increase anti-inflammatory factors IL-10 and TGF-β in vivo, while inhibiting LDH leakage and neuronal apoptosis through activation of STAT3 to antagonize I/R induction. Our results suggest that IL-27 may protect the brain from I/R injury through the gp130/STAT3 signaling pathway. Show less
no PDF DOI: 10.1007/s12031-021-01802-0
IL27
Kimberly Berke, Peter Sun, Edison Ong +12 more · 2021 · Frontiers in immunology · Frontiers · added 2026-04-24
Vaccines stimulate various immune factors critical to protective immune responses. However, a comprehensive picture of vaccine-induced immune factors and pathways have not been systematically collecte Show more
Vaccines stimulate various immune factors critical to protective immune responses. However, a comprehensive picture of vaccine-induced immune factors and pathways have not been systematically collected and analyzed. To address this issue, we developed VaximmutorDB, a web-based database system of vaccine immune factors (abbreviated as "vaximmutors") manually curated from peer-reviewed articles. VaximmutorDB currently stores 1,740 vaccine immune factors from 13 host species (e.g., human, mouse, and pig). These vaximmutors were induced by 154 vaccines for 46 pathogens. Top 10 vaximmutors include three antibodies (IgG, IgG2a and IgG1), Th1 immune factors (IFN-γ and IL-2), Th2 immune factors (IL-4 and IL-6), TNF-α, CASP-1, and TLR8. Many enriched host processes (e.g., stimulatory C-type lectin receptor signaling pathway, SRP-dependent cotranslational protein targeting to membrane) and cellular components (e.g., extracellular exosome, nucleoplasm) by all the vaximmutors were identified. Using influenza as a model, live attenuated and killed inactivated influenza vaccines stimulate many shared pathways such as signaling of many interleukins (including IL-1, IL-4, IL-6, IL-13, IL-20, and IL-27), interferon signaling, MARK1 activation, and neutrophil degranulation. However, they also present their unique response patterns. While live attenuated influenza vaccine FluMist induced significant signal transduction responses, killed inactivated influenza vaccine Fluarix induced significant metabolism of protein responses. Two different Yellow Fever vaccine (YF-Vax) studies resulted in overlapping gene lists; however, they shared more portions of pathways than gene lists. Interestingly, live attenuated YF-Vax simulates significant metabolism of protein responses, which was similar to the pattern induced by killed inactivated Fluarix. A user-friendly web interface was generated to access, browse and search the VaximmutorDB database information. As the first web-based database of vaccine immune factors, VaximmutorDB provides systematical collection, standardization, storage, and analysis of experimentally verified vaccine immune factors, supporting better understanding of protective vaccine immunity. Show less
📄 PDF DOI: 10.3389/fimmu.2021.639491
IL27
Yin-Huai Chen, Diane B Zastrow, Riley D Metcalfe +25 more · 2021 · The Journal of allergy and clinical immunology · Elsevier · added 2026-04-24
Biallelic variants in IL6ST, encoding GP130, cause a recessive form of hyper-IgE syndrome (HIES) characterized by high IgE level, eosinophilia, defective acute phase response, susceptibility to bacter Show more
Biallelic variants in IL6ST, encoding GP130, cause a recessive form of hyper-IgE syndrome (HIES) characterized by high IgE level, eosinophilia, defective acute phase response, susceptibility to bacterial infections, and skeletal abnormalities due to cytokine-selective loss of function in GP130, with defective IL-6 and IL-11 and variable oncostatin M (OSM) and IL-27 levels but sparing leukemia inhibitory factor (LIF) signaling. Our aim was to understand the functional and structural impact of recessive HIES-associated IL6ST variants. We investigated a patient with HIES by using exome, genome, and RNA sequencing. Functional assays assessed IL-6, IL-11, IL-27, OSM, LIF, CT-1, CLC, and CNTF signaling. Molecular dynamics simulations and structural modeling of GP130 cytokine receptor complexes were performed. We identified a patient with compound heterozygous novel missense variants in IL6ST (p.Ala517Pro and the exon-skipping null variant p.Gly484_Pro518delinsArg). The p.Ala517Pro variant resulted in a more profound IL-6- and IL-11-dominated signaling defect than did the previously identified recessive HIES IL6ST variants p.Asn404Tyr and p.Pro498Leu. Molecular dynamics simulations suggested that the p.Ala517Pro and p.Asn404Tyr variants result in increased flexibility of the extracellular membrane-proximal domains of GP130. We propose a structural model that explains the cytokine selectivity of pathogenic IL6ST variants that result in recessive HIES. The variants destabilized the conformation of the hexameric cytokine receptor complexes, whereas the trimeric LIF-GP130-LIFR complex remained stable through an additional membrane-proximal interaction. Deletion of this membrane-proximal interaction site in GP130 consequently caused additional defective LIF signaling and Stüve-Wiedemann syndrome. Our data provide a structural basis to understand clinical phenotypes in patients with IL6ST variants. Show less
no PDF DOI: 10.1016/j.jaci.2021.02.044
IL27
Xue Zhang, Su Li, Jinhui Wang +2 more · 2021 · Technology in cancer research & treatment · SAGE Publications · added 2026-04-24
Some evidence supports that the significance of inflammation is linked to a variety of tumors, including thyroid carcinoma. This work measured the preoperative serum inflammatory factors in thyroid tu Show more
Some evidence supports that the significance of inflammation is linked to a variety of tumors, including thyroid carcinoma. This work measured the preoperative serum inflammatory factors in thyroid tumors to explore their diagnostic values. Altogether 487 thyroid tumor patients were recruited, their neutrophil (NE), white blood cell (WBC), monocyte (MO), lymphocyte (LY), platelet (PLT) counts, together with monocyte/lymphocyte ratio (MLR), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), C-reactive protein (CRP), interleukin (IL)-1β, IL-2, IL-27, and tumor necrosis factor-α (TNF-α) levels were compared with controls. Afterward, the receiver operating characteristics (ROC) curve was plotted to further evaluate the values of these inflammatory markers in diagnosis. In addition, multivariable regression analysis was conducted to analyze all these inflammatory factors. Serum PLR, NLR, CRP, and IL-27 levels in thyroid adenoma (TA) and differentiated thyroid carcinoma (DTC) patients were higher than those in controls. Only the areas under the curve (AUC) for CRP and IL-27 were significant in the context of DTC. Besides, the AUC for IL-27 was significant between papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) groups, while that for NLR+PLR was also significant between PTC and healthy control groups. According to multivariable logistic regression analysis, IL-27 and CRP were associated with DTC. Inflammation plays an important role in TA and DTC progression. Preoperative IL-27 and CRP levels help to differentially diagnose DTC. Moreover, IL-27 assists in distinguishing FTC from PTC, and NLR+PLR is important for the differential diagnosis of PTC. Show less
📄 PDF DOI: 10.1177/1533033821990055
IL27
Fanyong Qu, Lina Wang, Caiyan Wang +3 more · 2021 · Cancer cell international · BioMed Central · added 2026-04-24
Chemoresistance is one of the major obstacles for cancer therapy in the clinic. Circular RNAs (circRNAs) are involved in the pathogenesis of esophageal squamous cell carcinoma (ESCC) and chemoresistan Show more
Chemoresistance is one of the major obstacles for cancer therapy in the clinic. Circular RNAs (circRNAs) are involved in the pathogenesis of esophageal squamous cell carcinoma (ESCC) and chemoresistance. This study aimed to explore the role and molecular mechanism of circ₀₀₀₆₁₆₈ in Taxol resistance of ESCC. The expression levels of circ₀₀₀₆₁₆₈, microRNA-194-5p (miR-194-5p) and jumonji domain containing 1C (JMJD1C) were measured by quantitative real-time polymerase chain reaction (qRT-PCR) or western blot. The half-inhibition concentration (IC Circ₀₀₀₆₁₆₈ and JMJD1C were upregulated and miR-194-5p was downregulated in ESCC tissues, ESCC cells, and Taxol-resistant cells. Functionally, knockdown of circ₀₀₀₆₁₆₈ or JMJD1C increased Taxol sensitivity of ESCC in vitro via inhibiting cell proliferation, migration and invasion, and promoting apoptosis. Moreover, circ₀₀₀₆₁₆₈ could directly bind to miR-194-5p and JMJD1C was verified as a direct target of miR-194-5p. Mechanically, circ₀₀₀₆₁₆₈ was a sponge of miR-194-5p to regulate JMJD1C expression in ESCC cells. Furthermore, JMJD1C overexpression reversed the promotive effect of circ₀₀₀₆₁₆₈ knockdown on Taxol sensitivity. Besides, circ₀₀₀₆₁₆₈ silence suppressed tumor growth in vivo. Circ₀₀₀₆₁₆₈ facilitated Taxol resistance in ESCC by regulating miR-194-5p/JMJD1C axis, providing a promising therapeutic target for ESCC chemotherapy. Show less
📄 PDF DOI: 10.1186/s12935-021-01984-y
JMJD1C
Yong Yang, Xinjing Zhang, Xiaoyan Zhang +12 more · 2021 · FEBS open bio · Wiley · added 2026-04-24
Leukemic stem cells (LSCs) comprise a very rare cell population that results in the development of acute myeloid leukemia. The selective targeting of drivers in LSCs with small molecule inhibitors hol Show more
Leukemic stem cells (LSCs) comprise a very rare cell population that results in the development of acute myeloid leukemia. The selective targeting of drivers in LSCs with small molecule inhibitors holds promise for treatment of acute myeloid leukemia. Recently, we reported the identification of inhibitors of the histone lysine demethylase JMJD1C that preferentially kill MLL rearranged acute leukemia cells. Here, we report the identification of jumonji domain modulator #7 (JDM-7). Surface plasmon resonance analysis showed that JDM-7 binds to JMJD1C and its family homolog JMJD1B. JDM-7 did not significantly suppress cell proliferation in liquid cell culture at higher doses, although it led to a significant decrease in semi-solid colony formation experiments at lower concentrations. Moreover, low doses of JDM-7 did not suppress the proliferation of erythroid progenitor cells. We identified that JDM-7 downregulates the LSC self-renewal gene HOXA9 in leukemia cells. We further found that the structure of JDM-7 is similar to that of tadalafil, a drug approved by the US Food and Drug Administration. Molecular docking and surface plasmon resonance analysis showed that tadalafil binds to JMJD1C. Moreover, similar to JDM-7, tadalafil suppressed colony formation of leukemia cells in semi-solid cell culture at a concentration that did not affect primary umbilical cord blood cells. In summary, we have identified JDM-7 and tadalafil as potential JMJD1C modulators that selectively inhibit the growth of LSCs. Show less
📄 PDF DOI: 10.1002/2211-5463.13054
JMJD1C
Chen-Guang Zhao, Jie Qin, Jia Li +9 more · 2021 · Stem cell research & therapy · BioMed Central · added 2026-04-24
Manipulation of neural stem and progenitor cells (NSPCs) is critical for the successful treatment of spinal cord injury (SCI) by NSPC transplantation, since their differentiation into neurons and olig Show more
Manipulation of neural stem and progenitor cells (NSPCs) is critical for the successful treatment of spinal cord injury (SCI) by NSPC transplantation, since their differentiation into neurons and oligodendrocytes can be inhibited by factors present in inflamed myelin. In this study, we examined the effects of LINGO-1 on spinal cord-derived NSPC (sp-NSPC) differentiation, the underlying mechanisms of action, and the functional recovery of mice after transplantation of manipulated cells. sp-NSPCs were harvested from female adult C57/BL6 mice after SCI induced with an NYU impactor. These cells were infected with lentiviral vectors containing LINGO-1 shRNA sequence or a scrambled control and transplanted into SCI mice. Tuj-1- and GFAP-positive cells were assessed by immunofluorescence staining. Wnt5a, p-JNK, JNK, and β-catenin expression was determined by Western blot and RT-qPCR. miRNAs were sequenced to detect changes in miRNA expression. Motor function was evaluated 0-35 days post-surgery by means of the Basso Mouse Scale (BMS) and by the rotarod performance test. We discovered that LINGO-1 shRNA increased neuronal differentiation of sp-NSPCs while decreasing astrocyte differentiation. These effects were accompanied by elevated Wnt5a protein expression, but unexpectedly, no changes in Wnt5a mRNA levels. miRNA-sequence analysis demonstrated that miR-15b-3p was a downstream mediator of LINGO-1 which suppressed Wnt5a expression. Transplantation of LINGO-1 shRNA-treated sp-NSPCs into SCI mice promoted neural differentiation, wound compaction, and motor function recovery. LINGO-1 shRNA promotes neural differentiation of sp-NSPCs and Wnt5a expression, probably by downregulating miR-15b-3p. Transplantation of LINGO-1 shRNA-treated NSPCs promotes recovery of motor function after SCI, highlighting its potential as a target for SCI treatment. Show less
📄 PDF DOI: 10.1186/s13287-021-02452-0
LINGO1
Bo Zhao, Guangping Li, Jianjun Peng +5 more · 2021 · Journal of cardiovascular translational research · Springer · added 2026-04-24
It is widely accepted that circular RNA (circRNA) plays an important role in cardiovascular diseases. Therefore, this experiment aimed to investigate the pathogenesis of circMACF1 in acute myocardial Show more
It is widely accepted that circular RNA (circRNA) plays an important role in cardiovascular diseases. Therefore, this experiment aimed to investigate the pathogenesis of circMACF1 in acute myocardial infarction (AMI). qRT-PCR and immunoblotting were used to detect the expression levels of circMACF1, miR-500b-5p, and epithelial membrane protein 1 (EMP1). The role of circMACF1, miR-500b-5p, and EMP1 in cardiomyocyte apoptosis was assessed using annexin V-FITC/PI. Echocardiographic assessment, serum creatine kinase MB (CK-MB) and lactate dehydrogenase (LDH), myocardial infarct size, and TUNEL staining were applied in our research. In the MI group, the expression levels of circMACF1 and EMP1 were decreased with the increasing expression level of miR-500b-5p. CircMACF1 upregulated the expression of EMP1 as a sponge of miR-500b-5p, and circMACF1 was a direct target of miR-500b-5p. CircMACF1 impaired the progression of AMI by modulating the miR-500b-5p/EMP1 axis. CircMACF1 may be a potential therapeutic target for treating AMI. Graphical Abstract CircMACF1 upregulated EMP1 expression by sponge miR-500b-5p. Show less
📄 PDF DOI: 10.1007/s12265-020-09976-5
MACF1
Wen Zhao, Danlei Yu, Zhen Chen +4 more · 2021 · Cancer letters · Elsevier · added 2026-04-24
The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrate Show more
The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line therapy. However, inevitable acquired resistance limits its long-term benefit to patients and is thus a significant clinical challenge. The current study focuses on studying the potential role of targeting MEK5-ERK5 signaling in overcoming acquired resistance to osimertinib. Osimertinib and other third generation EGFR inhibitors exerted a rapid and sustained suppressive effect on ERK5 phosphorylation primarily in EGFR-mutant NSCLC cell lines and lost this activity in some osimertinib-resistant cell lines. Osimertinib combined with either ERK5 or MEK5 inhibitors synergistically decreased the survival of osimertinib-resistant cell lines with enhanced induction of apoptosis primarily via augmenting Bim expression. Moreover, the combination effectively inhibited the growth of osimertinib-resistant xenografts in vivo. Together, these findings suggest the potential role of MEK5-ERK5 signaling in modulating development of acquired resistance to osimertinib and value of targeting this signaling as a potential strategy in overcoming acquired resistance to osimertinib and possibly other third generation EGFR inhibitors. Show less
no PDF DOI: 10.1016/j.canlet.2021.07.007
MAP2K5
Yue Wang, Weiyao Xiong, Shuangxia Zhao +2 more · 2021 · Stem cell research · Elsevier · added 2026-04-24
Hypertrophic cardiomyopathy is a hereditary disease with high incidence of sudden death and heart failure. Myosin-binding protein C3 (MYBPC3) is the most commonly mutation gene. Here, we report the es Show more
Hypertrophic cardiomyopathy is a hereditary disease with high incidence of sudden death and heart failure. Myosin-binding protein C3 (MYBPC3) is the most commonly mutation gene. Here, we report the establishment of two human induced pluripotent stem cell (iPSC) lines: one from a patient carrying a heterozygous c.1377delC mutation in MYBPC3 (c.1377delC: p.L460Wfs) and one from a healthy donor. The generated iPSC lines showed comparable pluripotent genes, demonstrated the capacity to differentiate into derivatives of all three germ layers and normal karyotypes. These lines are valuable for the mechanism research and drug development of hypertrophic cardiomyopathy. Show less
no PDF DOI: 10.1016/j.scr.2021.102594
MYBPC3
Qian-Li Yang, Lei Zuo, Zhi-Ling Ma +9 more · 2021 · Heart and vessels · Springer · added 2026-04-24
The mutation MYBPC3-E334K is a culprit mutation of hypertrophic cardiomyopathy (HCM). The pathogenicity of MYBPC3-E334K is conflicting in ClinVar because of the limited segregation data and the relati Show more
The mutation MYBPC3-E334K is a culprit mutation of hypertrophic cardiomyopathy (HCM). The pathogenicity of MYBPC3-E334K is conflicting in ClinVar because of the limited segregation data and the relatively high frequency in gnomAD (0.03% overall, with 0.3% in East Asians and 0.8% in Japanese). The main aim is to clarify the clinical importance and phenotype-genotype correlations in subjects with or without MYBPC3-E334K alone. The prevalence of MYBPC3-E334K was sequenced in 1017 HCM unrelated probands. The clinical features, morphology phenotypes, and electrical phenotypes were further analyzed according to the phenotype and genotype status in families with single-mutation MYBPC3-E334K. Nine of 1017 (0.88%) unrelated HCM probands were detected harboring MYBPC3-E334K, and three of them harbored a second variant in sarcomere protein gene. Family study and co-segregation analyses indicated that patients with single-mutation MYBPC3-E334K showed autosomal dominant mode of inheritance with incomplete penetrance. The overall disease penetrance was 52.6%, and the disease penetrance was higher in males than in females (100% in men vs 25% in women, p = 0.003). The mean age at diagnosis of males was approximately 25 years younger than females (36.57 ± 18.65 vs 62.33 ± 12.10, p = 0.062). The variant MYBPC3-E334K was classified as a likely pathogenic variant, and a second sarcomere variant did not reveal obvious cumulative effects. The patients harboring single-mutation MYBPC3-E334K had incomplete penetrance, and males demonstrated higher penetrance and early onset HCM than females. A second sarcomere variant did not reveal obvious cumulative effects. Show less
no PDF DOI: 10.1007/s00380-021-01834-x
MYBPC3
Shuang Ding, Wen Qi, Qi Xu +7 more · 2021 · Environmental pollution (Barking, Essex : 1987) · Elsevier · added 2026-04-24
In recent years, the incidence of lipid metabolism disorders in adolescents has gradually increased, and the effects of DEHP on lipid metabolism have received widespread attention. In this study, 463 Show more
In recent years, the incidence of lipid metabolism disorders in adolescents has gradually increased, and the effects of DEHP on lipid metabolism have received widespread attention. In this study, 463 adolescents aged 16-19 years were enrolled as subjects. This study analyzed the associations between the urinary levels of DEHP metabolites (MEHP, MEOHP, MEHHP, MECPP, MCMHP, and ∑DEHP) and BMI, WHR, WtHR, VAI, LAP, the plasma levels of lipids (TC, TG, HDL-C, and LDL-C), and the peripheral blood leukocyte mRNA levels of SREBP-2, SR-BI, LDLR, and NR1H3. Animal experiments were performed to confirm and expand findings. Wistar rats were administered DEHP at 0, 5, 50, and 500 mg/kg/d for 8 weeks. The serum and liver levels of TC, TG, HDL-C, and LDL-C, and the liver mRNA and protein levels of SREBP-2, SR-BI, LDLR, and NR1H3 were measured. The results showed that WHR, VAI, and LAP were significantly positively associated with the urinary levels of MECPP and ∑DEHP; the plasma HDL-C level was significantly negatively associated with the levels of MECPP, MCMHP and ∑DEHP; the peripheral blood leukocyte mRNA levels of SREBP-2, NR1H3, and LDLR were significantly positively correlated with the MCMHP level; and the SR-BI mRNA level was significantly positively correlated with the levels of MECPP and MCMHP in adolescents. Moreover, the results of animal experiments showed that DEHP exposure significantly increased the serum levels of TC, HDL-C, and LDL-C in 500 mg/kg/d group, as well as the liver levels of TC and HDL-C, up-regulated SREBP-2 mRNA and protein expression in 50 and 500 mg/kg/d groups. DEHP exposure significantly down-regulated SR-BI and NR1H3 protein expression in the liver of the 500 mg/kg/d group rats. Our findings indicate that DEHP exposure can affect lipid metabolism in adolescents by regulating the expression of lipid metabolism-related genes. Show less
no PDF DOI: 10.1016/j.envpol.2021.117570
NR1H3
Penglong Wang, Christina A Castellani, Jie Yao +29 more · 2021 · Human molecular genetics · Oxford University Press · added 2026-04-24
We conducted cohort- and race-specific epigenome-wide association analyses of mitochondrial deoxyribonucleic acid (mtDNA) copy number (mtDNA CN) measured in whole blood from participants of African an Show more
We conducted cohort- and race-specific epigenome-wide association analyses of mitochondrial deoxyribonucleic acid (mtDNA) copy number (mtDNA CN) measured in whole blood from participants of African and European origins in five cohorts (n = 6182, mean age = 57-67 years, 65% women). In the meta-analysis of all the participants, we discovered 21 mtDNA CN-associated DNA methylation sites (CpG) (P < 1 × 10-7), with a 0.7-3.0 standard deviation increase (3 CpGs) or decrease (18 CpGs) in mtDNA CN corresponding to a 1% increase in DNA methylation. Several significant CpGs have been reported to be associated with at least two risk factors (e.g. chronological age or smoking) for cardiovascular disease (CVD). Five genes [PR/SET domain 16, nuclear receptor subfamily 1 group H member 3 (NR1H3), DNA repair protein, DNA polymerase kappa and decaprenyl-diphosphate synthase subunit 2], which harbor nine significant CpGs, are known to be involved in mitochondrial biosynthesis and functions. For example, NR1H3 encodes a transcription factor that is differentially expressed during an adipose tissue transition. The methylation level of cg09548275 in NR1H3 was negatively associated with mtDNA CN (effect size = -1.71, P = 4 × 10-8) and was positively associated with the NR1H3 expression level (effect size = 0.43, P = 0.0003), which indicates that the methylation level in NR1H3 may underlie the relationship between mtDNA CN, the NR1H3 transcription factor and energy expenditure. In summary, the study results suggest that mtDNA CN variation in whole blood is associated with DNA methylation levels in genes that are involved in a wide range of mitochondrial activities. These findings will help reveal molecular mechanisms between mtDNA CN and CVD. Show less
no PDF DOI: 10.1093/hmg/ddab240
NR1H3
Yanhua Pu, Qian Zhao, Xuelin Men +2 more · 2021 · Life sciences · Elsevier · added 2026-04-24
MicroRNA-325 (miR-325) was significantly upregulated in diabetic atherosclerosis, while its specific role in atherosclerosis has not been established. The present study was set to probe the effects of Show more
MicroRNA-325 (miR-325) was significantly upregulated in diabetic atherosclerosis, while its specific role in atherosclerosis has not been established. The present study was set to probe the effects of miR-325 on the atherosclerosis progression and to explore the mechanisms. The ApoE miR-325 was elevated in arterial tissues of atherosclerotic mice, and miR-325 inhibition in mice reduced the contents of total cholesterol, triglyceride, low-density lipoprotein, and CRP, IL-6, IL-1β and TNF-ɑ levels in mouse serum. miR-325 inhibitor facilitated the cholesterol efflux and decreased the lipid content in RAW264.7 cells, and also diminished HA-VSMC viability. miR-325 targeted KDM1A to reduce SREBF1 expression, and further KDM1A suppression inhibited cholesterol efflux in RAW264.7 cells and the activation of PPARγ-LXR-ABCA1 pathway. miR-325 lowers SREBF1 expression by decreasing KDM1A expression, thereby inhibiting the activation of the PPARγ-LXR-ABCA1 pathway and thus promoting atherosclerosis. Show less
no PDF DOI: 10.1016/j.lfs.2021.119464
NR1H3
Lin Zhao, Wangrui Lei, Chao Deng +8 more · 2021 · Journal of cellular physiology · Wiley · added 2026-04-24
Liver X receptor α (LXRα; also known as NR1H3), an isoform of LXRs, is a member of the nuclear receptor family of transcription factors and plays essential roles in the transcriptional control of chol Show more
Liver X receptor α (LXRα; also known as NR1H3), an isoform of LXRs, is a member of the nuclear receptor family of transcription factors and plays essential roles in the transcriptional control of cholesterol homeostasis. Previous in-depth phenotypic analyses of mouse models with deficient LXRα have also demonstrated various physiological functions of this receptor within inflammatory responses. LXRα activation exerts a combination of metabolic and anti-inflammatory actions resulting in the modulation and the amelioration of inflammatory disorders. The tight "repercussions" between LXRα and inflammation, as well as cholesterol homeostasis, have suggested that LXRα could be pharmacologically targeted in pathologies such as atherosclerosis, acute lung injury, and Alzheimer's disease. This review gives an overview of the recent advances in understanding the roles of LXRα in inflammation and inflammation-associated diseases, which will help in the design of future experimental researches on the potential of LXRα and advance the investigation of LXRα as pharmacological inflammatory targets. Show less
no PDF DOI: 10.1002/jcp.30204
NR1H3
Yajuan Jiao, Ning Kong, Hua Wang +15 more · 2021 · Microbiology spectrum · added 2026-04-24
Emerging coronaviruses (CoVs) can cause severe diseases in humans and animals, and, as of yet, none of the currently available broad-spectrum drugs or vaccines can effectively control these diseases. Show more
Emerging coronaviruses (CoVs) can cause severe diseases in humans and animals, and, as of yet, none of the currently available broad-spectrum drugs or vaccines can effectively control these diseases. Host antiviral proteins play an important role in inhibiting viral proliferation. One of the isoforms of cytoplasmic poly(A)-binding protein (PABP), PABPC4, is an RNA-processing protein, which plays an important role in promoting gene expression by enhancing translation and mRNA stability. However, its function in viruses remains poorly understood. Here, we report that the host protein, PABPC4, could be regulated by transcription factor SP1 and broadly inhibits the replication of CoVs, covering four genera ( Show less
no PDF DOI: 10.1128/Spectrum.00908-21
PABPC4
Ju Gao, Luwen Wang, Xiaojia Ren +8 more · 2021 · The Journal of cell biology · added 2026-04-24
The in vivo physiological function of liquid-liquid phase separation (LLPS) that governs non-membrane-bound structures remains elusive. Among LLPS-prone proteins, TAR DNA-binding protein of 43 kD (TDP Show more
The in vivo physiological function of liquid-liquid phase separation (LLPS) that governs non-membrane-bound structures remains elusive. Among LLPS-prone proteins, TAR DNA-binding protein of 43 kD (TDP-43) is under intense investigation because of its close association with neurological disorders. Here, we generated mice expressing endogenous LLPS-deficient murine TDP-43. LLPS-deficient TDP-43 mice demonstrate impaired neuronal function and behavioral abnormalities specifically related to brain function. Brain neurons of these mice, however, did not show TDP-43 proteinopathy or neurodegeneration. Instead, the global rate of protein synthesis was found to be greatly enhanced by TDP-43 LLPS loss. Mechanistically, TDP-43 LLPS ablation increased its association with PABPC4, RPS6, RPL7, and other translational factors. The physical interactions between TDP-43 and translational factors relies on a motif, the deletion of which abolished the impact of LLPS-deficient TDP-43 on translation. Our findings show a specific physiological role for TDP-43 LLPS in the regulation of brain function and uncover an intriguing novel molecular mechanism of translational control by LLPS. Show less
no PDF DOI: 10.1083/jcb.202101019
PABPC4
Ruixia Zhu, Yating Zhao, Dandan Tian +3 more · 2021 · American journal of translational research · added 2026-04-24
In the past decade, an increasing number of genome-wide association studies (GWASs) have been applied to ischemic stroke (IS) susceptibility and recovery. In our study, six GWAS-linked hot loci (
no PDF
PATJ
Yuesheng Lv, Wenjing Zhang, Jinyao Zhao +13 more · 2021 · Signal transduction and targeted therapy · Nature · added 2026-04-24
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the Show more
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the splicing factor SRSF1 as an autophagy suppressor. Specifically, SRSF1 inhibits autophagosome formation by reducing the accumulation of LC3-II and numbers of autophagosomes in different cell lines. Mechanistically, SRSF1 promotes the splicing of the long isoform of Bcl-x that interacts with Beclin1, thereby dissociating the Beclin1-PIK3C3 complex. In addition, SRSF1 also directly interacts with PIK3C3 to disrupt the interaction between Beclin1 and PIK3C3. Consequently, the decrease of SRSF1 stabilizes the Beclin1 and PIK3C3 complex and activates autophagy. Interestingly, SRSF1 can be degraded by starvation- and oxidative stresses-induced autophagy through interacting with LC3-II, whereas reduced SRSF1 further promotes autophagy. This positive feedback is critical to inhibiting Gefitinib-resistant cancer cell progression both in vitro and in vivo. Consistently, the expression level of SRSF1 is inversely correlated to LC3 level in clinical cancer samples. Our study not only provides mechanistic insights of alternative splicing in autophagy regulation but also discovers a new regulatory role of SRSF1 in tumorigenesis, thereby offering a novel avenue for potential cancer therapeutics. Show less
no PDF DOI: 10.1038/s41392-021-00495-6
PIK3C3
Yuting Zhao, Zhongju Zou, Daxiao Sun +5 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
A key mediator of macroautophagy/autophagy induction is the class III phosphatidylinositol 3-kinase complex I (PtdIns3K-C1) consisting of PIK3C3/VPS34, PIK3R4/VPS15, BECN1, and ATG14. Although several Show more
A key mediator of macroautophagy/autophagy induction is the class III phosphatidylinositol 3-kinase complex I (PtdIns3K-C1) consisting of PIK3C3/VPS34, PIK3R4/VPS15, BECN1, and ATG14. Although several proteins are known to enhance or decrease PtdIns3K-C1 activity, our understanding of the molecular regulation of PtdIns3K-C1 is still incomplete. Previously, we identified a Golgi-associated protein, GLIPR2, in a screen for proteins that interact with amino acids 267-284 of BECN1, a region of BECN1 sufficient to induce autophagy when fused to a cell penetrating leader sequence. In this study, we used CRISPR-Cas9-mediated depletion of GLIPR2 in cells and mice to investigate the role of GLIPR2 in the regulation of autophagy and PtdIns3K-C1 activity. Depletion of GLIPR2 in HeLa cells increased autelophagic flux and generation of phosphatidylinositol 3-phosphate (PtdIns3P). Show less
no PDF DOI: 10.1080/15548627.2020.1847798
PIK3C3
S L Wang, X W Dong, F Zhao +1 more · 2021 · Journal of biological regulators and homeostatic agents · added 2026-04-24
no PDF DOI: 10.23812/20-304-L
RGS17
A N Zhao, H J Yin, M G Fan +3 more · 2021 · Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn121094-20200622-00354
SNAI1
Allan R Brasier, Dianhua Qiao, Yingxin Zhao · 2021 · Frontiers in pharmacology · Frontiers · added 2026-04-24
Disruption of the lower airway epithelial barrier plays a major role in the initiation and progression of chronic lung disease. Here, repetitive environmental insults produced by viral and allergens t Show more
Disruption of the lower airway epithelial barrier plays a major role in the initiation and progression of chronic lung disease. Here, repetitive environmental insults produced by viral and allergens triggers metabolic adaptations, epithelial-mesenchymal plasticity (EMP) and airway remodeling. Epithelial plasticity disrupts epithelial barrier function, stimulates release of fibroblastic growth factors, and remodels the extracellular matrix (ECM). This review will focus on recent work demonstrating how the hexosamine biosynthetic pathway (HBP) links innate inflammation to airway remodeling. The HBP is a core metabolic pathway of the unfolded protein response (UPR) responsible for protein N-glycosylation, relief of proteotoxic stress and secretion of ECM modifiers. We will overview findings that the IκB kinase (IKK)-NFκB pathway directly activates expression of the Show less
no PDF DOI: 10.3389/fphar.2021.808735
SNAI1
Yangyang Yang, Binggong Zhao, Linlin Lv +3 more · 2021 · Cell death discovery · Nature · added 2026-04-24
F-box and leucine-rich repeat protein 10 (FBXL10) has been reported to play a regulatory role in the initiation and development of breast cancer. Bioinformatics analyses revealed that FBXL10 may invol Show more
F-box and leucine-rich repeat protein 10 (FBXL10) has been reported to play a regulatory role in the initiation and development of breast cancer. Bioinformatics analyses revealed that FBXL10 may involve in the process of cytoskeleton organization. This research aimed to investigate the function of FBXL10 in epithelial-mesenchymal transition (EMT) and metastasis of breast cancer, and tried to reveal the molecular mechanism involved in this issue. Functional experiments in vitro revealed that FBXL10 promoted the migration and invasion of breast cancer cells through inhibiting E-cadherin expression and inducing EMT. Mechanical studies revealed that FBXL10 could specifically interact with SNAI1, but not Slug or ZEB1. And it promoted the transcriptional repression activity of SNAI1 on CDH1 in breast cancer cells. Furthermore, FBXL10 had a positive role for the deacetylation of SNAI1 by facilitating the interaction between SNAI1 and HDAC1, a dominating deacetylase of SNAI1. And the deacetylated SNAI1 showed a more suppressive ability to inhibit the transcription of E-cadherin. Moreover, mouse models were also conducted to confirm the effect of FBXL10 on the lung metastasis of breast cancer in vivo. Totally, our data revealed that FBXL10 served as a pro-metastatic factor in breast cancer via repressing the expression of E-cadherin and inducing EMT. It may provide a novel regulatory axis in the EMT of breast cancer. Show less
no PDF DOI: 10.1038/s41420-021-00722-7
SNAI1
Tianli Shen, Chenyang Yue, Xingjie Wang +6 more · 2021 · Experimental cell research · Elsevier · added 2026-04-24
Metastatic recurrence remains a major cause of colorectal cancer (CRC) mortality. In this study, we investigated the mechanistic role of nuclear factor of activated T cells 1 (NFATc1) in CRC metastasi Show more
Metastatic recurrence remains a major cause of colorectal cancer (CRC) mortality. In this study, we investigated the mechanistic role of nuclear factor of activated T cells 1 (NFATc1) in CRC metastasis. First, we explored the potential role of NFATc1 in CRC using bioinformatics and hypothesized that NFATc1 might play different roles at different stages of CRC development. Then, we examined the relative expression of NFATc1 in 25 CRC tissues and adjacent normal tissues, and further analyzed the correlation between NFATc1 expression levels and clinical stages in 120 CRC patients. The role of NFATc1 in CRC metastasis and the molecular mechanisms were investigated in both in vitro and in vivo models. Our results showed that the expression of NFATc1 was increased in metastatic CRC tissues and positively associated with clinical stages (stage I vs. stage II, III or IV) of CRC. Overexpression of NFATc1 promoted CRC cell migration, invasion, and epithelial-mesenchymal transition (EMT). Moreover, SNAI1 was verified as the direct transcriptional target of NFATc1 and interacted with SLUG to promote EMT. Remarkably, our lung and liver metastasis mouse model demonstrated that NFATc1 overexpression accelerated CRC metastasis, and treatment with FK506, a calcineurin-NFAT pathway inhibitor, could suppress CRC metastasis in vivo. Taken together, our findings suggest that NFATc1 could transcriptionally activate SNAI1, which in turn interacts with SLUG to mediate EMT to promote CRC metastasis. Thus, making NFATc1 a promising therapeutic target in the treatment of metastatic CRC. Show less
no PDF DOI: 10.1016/j.yexcr.2021.112854
SNAI1
Hongyan Cui, Yue Wang, Lili Chen +8 more · 2021 · Journal of controlled release : official journal of the Controlled Release Society · Elsevier · added 2026-04-24
Molecular insights into tumorigenesis have uncovered intimate correlation of SNAI1 with tumor malignancy. Herein, to explore merits of SNAI1-knockdown in tumor therapy, we harnessed RNA interference t Show more
Molecular insights into tumorigenesis have uncovered intimate correlation of SNAI1 with tumor malignancy. Herein, to explore merits of SNAI1-knockdown in tumor therapy, we harnessed RNA interference tool (shSNAI1), together with chemotherapeutic doxorubicin. Owing to abundant hydroxyl groups, pullulan was attempted to be covalently conjugated with a multiple of functional moieties, including positively-charged oligoethylenimine components for electrostatic entrapment of polyanionic shSNAI1 and hydrophobic components for entrapment of lipophilic doxorubicin. Notably, the aforementioned covalent conjugations were tailored to be detachable in response to intracellular reducing microenvironment owing to redox disulfide linkage, thereby accounting for selective intracellular liberation of the therapeutic payloads. Moreover, the surface of nanomedicine was modified with hyaluronic acid, endowing not only excellent biocompatibilities but active tumor-targeting function due to its receptors (CD44) overexpressed on tumor cells. Subsequent investigations approved appreciably targeted co-delivery of shSNAI1 and doxorubicin into solid lung tumors via systemic administration and demonstrated critical contribution of SNAI1-knockdown in amplifying chemotherapeutic potencies. Show less
no PDF DOI: 10.1016/j.jconrel.2021.07.039
SNAI1
Dianhua Qiao, Melissa Skibba, Xiaofang Xu +3 more · 2021 · American journal of physiology. Lung cellular and molecular physiology · added 2026-04-24
The paramyxoviridae, respiratory syncytial virus (RSV), and murine respirovirus are enveloped, negative-sense RNA viruses that are the etiological agents of vertebrate lower respiratory tract infectio Show more
The paramyxoviridae, respiratory syncytial virus (RSV), and murine respirovirus are enveloped, negative-sense RNA viruses that are the etiological agents of vertebrate lower respiratory tract infections (LRTIs). We observed that RSV infection in human small airway epithelial cells induced accumulation of glycosylated proteins within the endoplasmic reticulum (ER), increased glutamine-fructose-6-phosphate transaminases (GFPT1/2) and accumulation of uridine diphosphate (UDP)- Show less
no PDF DOI: 10.1152/ajplung.00127.2021
SNAI1
Danhui Liu, Yuzhen Liu, Bo Qi +3 more · 2021 · Cancer medicine · Wiley · added 2026-04-24
Histone deacetylases (HDACs) have been demonstrated to be aberrantly activated in tumorigenesis and cancer development. Thus, HDAC inhibitors (HDACIs) are considered to be promising anti-cancer therap Show more
Histone deacetylases (HDACs) have been demonstrated to be aberrantly activated in tumorigenesis and cancer development. Thus, HDAC inhibitors (HDACIs) are considered to be promising anti-cancer therapeutics. However, recent studies have shown that HDACIs promote the migration of many cancer cells. Therefore, there is a need to elucidate the underlying mechanisms of HDACIs on cancer cell migration to establish a combination therapy that overcomes HDACI-induced cell migration. KYSE-150 and EC9706 cells were treated differently. Effects of drugs and siRNA treatment on tumor cell migration and cell signaling pathways were investigated by transwell migration assy. Gene expression for SNAI2 was tested by RT-qPCR. Western blot analysis was employed to detect the level of E-cadherin, β-catenin, vimentin,Slug,ERK1/2, H3, PAI-1 and BRD4. The effect of drugs on cell morphology was evaluated through phase-contrast microscopic images. TSA promotes epithelial-mesenchymal transition (EMT) in ESCC cells by downregulating the epithelial marker E-cadherin and upregulating mesenchymal markers β-catenin, vimentin, Slug, and PAI-1. Knockdown of Slug by siRNA or inhibition of PAI-1 clearly suppressed TSA-induced ESCC cell migration and resulted in the reversal of TSA-triggered E-cadherin, β-catenin, and vimentin expression. However, no crosstalk between Slug and PAI-1 was observed in TSA-treated ESCC cells. Blocking ERK1/2 activation also inhibited TSA-induced ESCC cell migration, EMT, and upregulation of Slug and PAI-1 levels in ESCC cells. Interestingly, inhibition of BRD4 suppressed TSA-induced ESCC cell migration and attenuated TSA-induced ERK1/2 activation and upregulation of Slug and PAI-1 levels. Our data indicate the existence of at least two separable ERK1/2-dependent signaling pathways in TSA-mediated ESCC cell migration: an ERK1/2-Slug branch and an ERK1/2-PAI-1 branch. Both branches of TSA-induced ESCC cell migration appear to favor the EMT process, while BRD4 is responsible for two separable ERK1/2-dependent signaling pathways in TSA-mediated ESCC cell migration. Show less
no PDF DOI: 10.1002/cam4.4059
SNAI1